- Home
- ITRM vs TPST Comparison
ITRM vs TPST Comparison
Compare ITRM & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- TPST
- Stock Information
- Founded
- ITRM 2015
- TPST 2011
- Country
- ITRM Ireland
- TPST United States
- Employees
- ITRM N/A
- TPST N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- ITRM Health Care
- TPST Health Care
- Exchange
- ITRM Nasdaq
- TPST Nasdaq
- Market Cap
- ITRM 40.0M
- TPST 45.5M
- IPO Year
- ITRM 2018
- TPST N/A
- Fundamental
- Price
- ITRM $0.73
- TPST $11.83
- Analyst Decision
- ITRM Strong Buy
- TPST Hold
- Analyst Count
- ITRM 1
- TPST 3
- Target Price
- ITRM $9.00
- TPST $30.00
- AVG Volume (30 Days)
- ITRM 821.8K
- TPST 45.9K
- Earning Date
- ITRM 11-13-2025
- TPST 11-11-2025
- Dividend Yield
- ITRM N/A
- TPST N/A
- EPS Growth
- ITRM N/A
- TPST N/A
- EPS
- ITRM N/A
- TPST N/A
- Revenue
- ITRM N/A
- TPST N/A
- Revenue This Year
- ITRM N/A
- TPST N/A
- Revenue Next Year
- ITRM $482.25
- TPST N/A
- P/E Ratio
- ITRM N/A
- TPST N/A
- Revenue Growth
- ITRM N/A
- TPST N/A
- 52 Week Low
- ITRM $0.61
- TPST $5.35
- 52 Week High
- ITRM $3.02
- TPST $20.67
- Technical
- Relative Strength Index (RSI)
- ITRM 50.74
- TPST 64.42
- Support Level
- ITRM $0.66
- TPST $10.26
- Resistance Level
- ITRM $0.83
- TPST $11.25
- Average True Range (ATR)
- ITRM 0.05
- TPST 0.61
- MACD
- ITRM 0.01
- TPST 0.13
- Stochastic Oscillator
- ITRM 41.24
- TPST 92.81
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.